SAGES Magazine

THE SOUTH AFRICAN GASTROENTEROLOGY REVIEW 2023 | VOLUME 21 | ISSUE 1 | 14 Rapid Release 1 Modified Release 1 At last... a new chemical entity your patients can start on once-daily and stay on once-daily. 1,2 One capsule daily 1 The first once-a-day PPI with novel dual delayed release technology. 1,2 24 hour heartburn free days are achievable. 1,2 1 - 2 h o u r s 1 4 - 5 h o u r s 1 PPI = Proton Pump Inhibitor REFERENCES: 1. Dexilant Professional Information. Takeda (Pty) Ltd, South Africa; August 2021. 2. Metz DC, Howden CW, Perez MC, et al. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther 2009;29:742-754. S4 DEXILANT ® 30 mg modified-release capsules, hard. Reg. No. 48/11.4.3/0695. Each capsule contains 30 mg of dexlansoprazole. S4 DEXILANT ® 60 mg modified-release capsules, hard. Reg. No. 48/11.4.3/0696. Each capsule contains 60 mg of dexlansoprazole. For full prescribing information refer to the professional information approved by the medicines regulatory authority. TAKEDA (Pty) Ltd. Reg. No.: 1982/011215/07. Building A, Monte Circle, 64 Montecasino Boulevard, Fourways, 2191, South Africa. Tel: +27 (0) 11 514 3000. Fax: +27 (0) 11 514 3001. Marketed by Adcock Ingram Limited. Reg. No. 2007/019928/07. Private Bag X 69, Bryanston, 2021, South Africa. Tel +27 (0) 11 635 0000. www.adcock.com . C/APROM/ZA/DEXI/0035